[1. O’Brien MN, Jiang W, Wang Y, Loffredo DM. Challenges and opportunities in the development of complex generic long-acting injectable drug products. J Control Release. 2021; 336:144-158.10.1016/j.jconrel.2021.06.01734126170]Search in Google Scholar
[2. Chazin H, Woo J, Han J, Grosser S, Luan J. FDA’s Generic Drug Program: Decreasing Time to Approval and Number of Review Cycles. Ther Innov Regul Sci. 2020;54(4):758-763.10.1007/s43441-019-00016-232557293]Search in Google Scholar
[3. Woo J, Luan JJ, Li Z, Grosser S, Peters J, Chazin H. Abbreviated New Drug Applications: Generic Drug User Fee Amendments Act Analysis of Application Quality Metrics. Ther Innov Regul Sci. 2019;53(5):696-700.10.1177/216847901880619230360656]Search in Google Scholar
[4. Food and Drug Administration. Silver spring: The competitive Generic Therapy; [updated 2021 Aug 06; cited 2021 Aug 12]. Available from: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/competitive-generic-therapies]Search in Google Scholar
[5. Food and Drug Administration. Silver spring: Patent Challenge exclusivity; [updated 2021 Aug 02; cited 2021 Aug 10]. Available from: https://www.fda.gov/drugs/cder-small-business-industry-assistance-sbia/small-business-assistance-180-day-generic-drug-exclusivity]Search in Google Scholar
[6. Gurgula O. Strategic Patenting by Pharmaceutical Companies–Should Competition Law Intervene?. IIC-International Review of Intellectual Property and Competition Law. 2020;51(9):1062-85.10.1007/s40319-020-00985-0759214033132411]Search in Google Scholar
[7. Sahragardjoonegani B, Beall RF, Kesselheim AS, Hollis A. Repurposing existing drugs for new uses: a cohort study of the frequency of FDA-granted new indication exclusivities since 1997. Journal of pharmaceutical policy and practice. 2021;14(1):1-8.10.1186/s40545-020-00282-8778060733397471]Search in Google Scholar
[8. Holman CM, Minssen T, Solovy EM. Patentability standards for follow-on pharmaceutical innovation. Biotechnology Law Report. 2018;37(3):131-61.10.1089/blr.2018.29073.cmh]Search in Google Scholar
[9. Hering S, Loretz B, Friedli T, Lehr CM, Stieneker F. Can lifecycle management safeguard innovation in the pharmaceutical industry? Drug Discov Today. 2018;23(12):1962-1973.10.1016/j.drudis.2018.10.00830342247]Search in Google Scholar
[10. Xie J. Horizontal Shareholdings and Paragraph IV Generic Entry in the U.S. Pharmaceutical Industry. The Antitrust Bulletin. 2021;66(1):100-112.10.1177/0003603X20985797]Search in Google Scholar
[11. Beall RF, Ronksley PE, Wick J, Darrow JJ, Sarpatwari A, Kesselheim AS. Comparing Onset of Biosimilar Versus Generic Competition in the United States. Clin Pharmacol Ther. 2020;108(6):1308-1314.10.1002/cpt.198132621540]Search in Google Scholar
[12. Gupta R, Shah ND, Ross JS. Generic drugs in the United States: policies to address pricing and competition. Clinical Pharmacology & Therapeutics. 2019;105(2):329-37.10.1002/cpt.1314635535630471089]Search in Google Scholar
[13. Olson LM, Wendling BW. Estimating the causal effect of entry on generic drug prices using Hatch–Waxman exclusivity. Review of Industrial Organization. 2018; 53(1):139-72.10.1007/s11151-018-9627-y]Search in Google Scholar
[14. Bernstein JJJ, Holt GB, Bernstein J. Price dispersion of generic medications. PLoS One. 2019; 14(11): e0225280.10.1371/journal.pone.0225280686093231738807]Search in Google Scholar
[15. Food and Drug Administration. Silver spring: Total Generic’s approved;[updated 2021 Sep 23; cited 2021 Aug 05]. Available from: https://www.accessdata.fda.gov/scripts/cder/daf/]Search in Google Scholar
[16. Food and Drug Administration. Silver spring: First generic drugs;[updated 2021 Sep 28; cited 2021 Aug 07]. Available from: https://www.fda.gov/drugs/drug-and-biologic-approval-and-ind-activity-reports/first-generic-drug-approvals]Search in Google Scholar
[17. Food and Drug Administration. Silver spring: Patent Challenge exclusivity; [updated 2021 Aug 02; cited 2021 Aug 10]. Available from: https://www.fda.gov/drugs/abbreviated-new-drug-application-anda/patent-certifications-and-suitability-petitions]Search in Google Scholar
[18. Food and Drug Administration. Silver spring: The competitive Generic Therapy; [updated 2021 Aug 06; cited 2021 Aug 12]. Available from: https://www.fda.gov/drugs/generic-drugs/competitive-generic-therapy-approvals]Search in Google Scholar
[19. United States District Court for the District of Delaware. Generic drugs Patent litigations; [updated 2021 Sep 25; cited 2021 Aug 02]. Available from: https://www.ded.uscourts.gov/]Search in Google Scholar
[20. Food and Drug Administration. Silver spring: orange book; [updated 2021 Aug 06; cited 2021 Aug 09]. Available from: https://www.accessdata.fda.gov/scripts/cder/ob/index.cfm]Search in Google Scholar
[21. Beall RF, Darrow JJ, Kesselheim AS. A method for approximating future entry of generic drugs. Value in Health. 2018;21(12):1382-9.10.1016/j.jval.2018.04.182730502781]Search in Google Scholar
[22. Lee Y, Fong EA. Patent lifecycle management strategies in open innovation projects. Drug Discovery Today. 2020;25(10):1782-5.10.1016/j.drudis.2020.06.01932592662]Search in Google Scholar
[23. Darrow JJ, Beall RF, Kesselheim AS. The Generic Drug Industry Embraces a Faster, Cheaper Pathway for Challenging Patents. Appl Health Econ Health Policy. 2019; 17(1):47-54.10.1007/s40258-018-0420-830141133]Search in Google Scholar
[24. Agranat I, Marom H. In Defense of Secondary Pharmaceutical Patents in Drug Discovery and Development. ACS Med Chem Lett. 2020; 11(2):91-98.10.1021/acsmedchemlett.9b00497710698532280427]Search in Google Scholar
[25. Socal MP, Parasrampuria S, Anderson GF. Modifying the Criteria for Granting Orphan Drug Market Exclusivity. Value Health. 2020; 23(11):1470-1476.10.1016/j.jval.2020.08.00433127018]Search in Google Scholar
[26. Kerr KW, Glos LJ. Effective Market Exclusivity of New Molecular Entities for Rare and Non-rare Diseases. Pharmaceut Med. 2020; 34(1):19-29.10.1007/s40290-019-00317-9]Search in Google Scholar
[27. Beall RF, Kesselheim AS, Sarpatwari A. New Drug Formulations and Their Respective Generic Entry Dates. J Manag Care Spec Pharm. 2019;25(2):218-224.10.18553/jmcp.2019.25.2.21830698097]Search in Google Scholar
[28. Fermont I. Pharmacovigilance strategy: opportunities for cross-national learning. Isr J Health Policy Res. 2019; 8(1):54.10.1186/s13584-019-0319-3658255731217025]Search in Google Scholar
[29. Bejarano A, Hewa Nadungodage C, Wang F, Catlin AC, Hoag SW. Decision Support for Excipient Risk Assessment in Pharmaceutical Manufacturing. AAPS PharmSciTech. 2019; 20(6):223.10.1208/s12249-019-1440-x31214878]Search in Google Scholar
[30. Leistner A, Haerling S, Kreher JD, Becker I, Jung D, Holzgrabe U. Risk assessment report of potential impurities in cetirizine dihydrochloride. J Pharm Biomed Anal. 2020; 189:113425.10.1016/j.jpba.2020.11342532599488]Search in Google Scholar
[31. Ermer J, Aguiar D, Boden A, Ding B, Obeng D, Rose M, Vokrot J. Lifecycle management in pharmaceutical analysis: How to establish an efficient and relevant continued performance monitoring program. J Pharm Biomed Anal. 2020; 181:113051.10.1016/j.jpba.2019.11305131962246]Search in Google Scholar
[32. Charoo NA. Converging Generic Drug Product Development: Bioequivalence Design and Reference Product Selection. Clin Pharmacokinet. 2020; 59(11):1335-1355.10.1007/s40262-020-00912-z32757104]Search in Google Scholar
[33. Zhao L, Kim MJ, Zhang L, Lionberger R. Generating Model Integrated Evidence for Generic Drug Development and Assessment. Clin Pharmacol Ther. 2019; 105(2):338-349.10.1002/cpt.128230414386]Search in Google Scholar
[34. Rattan AK. Data Integrity: History, Issues, and Remediation of Issues. PDA J Pharm Sci Technol. 2018; 72(2):105-116.10.5731/pdajpst.2017.00776529158286]Search in Google Scholar
[35. Fermaglich LJ, Chen R, Kim CY, Chuh EE, Thomas T, Shetty D, Lee J, Young J, Fan Y. Common Filing Deficiencies in Abbreviated New Drug Applications Containing Clinical Endpoint Studies. Ther Innov Regul Sci. 2019; 53(1):81-85.10.1177/216847901876929829719976]Search in Google Scholar
[36. Kugener VF, Freedland ES, Maynard KI, Aimer O, Webster PS, Salas M, Gossell-Williams M. Enhancing Pharmacovigilance from the US Experience: Current Practices and Future Opportunities. Drug Safety. 2021;1-0.10.1007/s40264-021-01078-8812309933993430]Search in Google Scholar
[37. Peng L, Xiao K, Ottaviani S, Stebbing J, Wang YJ. A real-world disproportionality analysis of FDA Adverse Event Reporting System (FAERS) events for baricitinib. Expert Opin Drug Saf. 2020; 19(11):1505-1511.10.1080/14740338.2020.179997532693646]Search in Google Scholar
[38. Wittayanukorn S, Rosenberg M, Schick A, Hu M, Wang Z, Babiskin A, Lionberger R, Zhao L. Factors that have an Impact on Abbreviated New Drug Application (ANDA) Submissions. Ther Innov Regul Sci. 2020; 54(6):1372-1381.10.1007/s43441-020-00163-x32495310]Search in Google Scholar